CliffBio
small molecule

BLEOMYCIN SULFATE

BLEOMYCIN SULFATE

Loss of exclusivity—loss of exclusivity
CompanyMeitheal Pharmaceuticals, Inc. →See this company's full patent-cliff portfolio

Drug detail

Brand nameBLEOMYCIN SULFATE
Active ingredientBLEOMYCIN SULFATE
StrengthEQ 30 UNITS BASE/VIAL
Dosage formINJECTABLE
RouteINJECTION
ModalitySmall molecule
FDA approvalApril 2018
Marketing statusRX

More from Meitheal Pharmaceuticals, Inc.

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.

BLEOMYCIN SULFATE patent cliff — loss of exclusivity — | CliffBio